First: the lipolytic effect in animal models (in rats and mice on a high-fat diet) did not translate to humans with stabilized obesity
Ipamorelin works through a different receptor pathway that triggers GH release more directly
Both use the same main drug, but the rules for prescribing and who can get them are not the same
The management of obesity is rapidly evolving with new pharmacological treatments leading to weight loss similar to that achieved with weight loss surgery
Specifically, several factors which can cause aggregation include but are not limited to shaking, shearing, temperature, pH level, and protein concentration 23, 24
These GI effects are a class-wide phenomenon inherent to GLP-1 receptor agonism and are managed through gradual dose escalation starting at a low dose and increasing at defined intervals to allow gastrointestinal adaptation